Benign Prostatic Hyperplasia
Conditions
Interventions
Tamusulosin 8 weeks 0.2 mg once a day
Naftopidil 8 weeks 75 mg once a day
Sponsors
Matsushita Urologocal Clinic
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1)The patients aged more than 50 years who written informed consent was obtained . 2)The patients who had a diagnosis of bengin prostatic hyperplasia with non-treatment. 3)I-PSS total score higher than 8 and QOL score higher than 2
Exclusion criteria
Exclusion criteria: 1)Patients who have taken a medicine that influence on the urination function. 2)Patients with suspected prostate cancer. 3)Patients with suspected Neurogenic Bladder. 4)Patients with urethral stricture. 5)Patients who gave radiotherapy in the pelvis. 6)Patients with urinary tract infection, calculus urinary, cystitis interstitial. 7)Patients with serious impaired liver function, serious renal dysfunction, serious heart disorder. 8)Patients with orthostatic hypotension. 9)Patients with myasthenia gravis. 10)Maximum urinary flow rate=>15mL/s 11)The inappropriate patients who is judged by urologist.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International Prostate Symptom Score BPH Impact Index | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Pressure | — |
Countries
Japan
Contacts
Public ContactMasami Matsushita
Matsushita Urologocal Clinic Department of Urology
Outcome results
None listed